Key statistics
52-week range
Open | 1.89 |
---|---|
High | 1.89 |
Low | 1.67 |
Bid | 1.52 |
Offer | 1.89 |
Previous close | 1.86 |
Average volume | 270.24k |
---|---|
Shares outstanding | 55.56m |
Free float | 32.51m |
P/E (TTM) | -- |
Market cap | 103.34m USD |
EPS (TTM) | -0.3109 USD |
Data delayed at least 15 minutes, as of Jul 18 2025 21:00 BST.
More ▼
- Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference
- Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China
- Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
- Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
- Connect Biopharma to Present at Two Upcoming Investor Conferences in June
- Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference
- Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update
- Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD
- Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
More ▼